Compare Stocks: ACRV, CABA, PRLD, and FULC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.76 +2.3%	$1.99	$1.27 ▼ $3.56	$73.71M	1.91	306,773 shs	114,455 shs
CABA Cabaletta Bio	$1.55 -4.3%	$2.62	$1.51 ▼ $4.23	$274.66M	3.48	5.77 million shs	6.73 million shs
FULC Fulcrum Therapeutics	$3.67	$3.78	$2.83 ▼ $15.74	$280.01M	2.63	1.57 million shs	1.23 million shs
PRLD Prelude Therapeutics	$3.32 +2.8%	$4.86	$1.16 ▼ $6.83	$257.77M	0.97	539,579 shs	400,250 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.33%	-5.88%	-3.83%	+0.57%	-6.88%
CABA Cabaletta Bio	-4.32%	-20.51%	-40.38%	-45.23%	-46.55%
FULC Fulcrum Therapeutics	0.00%	-2.13%	-2.91%	+0.55%	-61.93%
PRLD Prelude Therapeutics	+2.79%	-14.43%	-26.55%	-20.95%	+144.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.76 +2.3%	$1.99	$1.27 ▼ $3.56	$73.71M	1.91	306,773 shs	114,455 shs
CABA Cabaletta Bio	$1.55 -4.3%	$2.62	$1.51 ▼ $4.23	$274.66M	3.48	5.77 million shs	6.73 million shs
FULC Fulcrum Therapeutics	$3.67	$3.78	$2.83 ▼ $15.74	$280.01M	2.63	1.57 million shs	1.23 million shs
PRLD Prelude Therapeutics	$3.32 +2.8%	$4.86	$1.16 ▼ $6.83	$257.77M	0.97	539,579 shs	400,250 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+2.33%	-5.88%	-3.83%	+0.57%	-6.88%
CABA Cabaletta Bio	-4.32%	-20.51%	-40.38%	-45.23%	-46.55%
FULC Fulcrum Therapeutics	0.00%	-2.13%	-2.91%	+0.55%	-61.93%
PRLD Prelude Therapeutics	+2.79%	-14.43%	-26.55%	-20.95%	+144.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	667.05% Upside
CABA Cabaletta Bio	2.89	Moderate Buy	$15.60	906.45% Upside
FULC Fulcrum Therapeutics	1.75	Reduce	$8.20	123.43% Upside
PRLD Prelude Therapeutics	2.57	Moderate Buy	$8.75	163.55% Upside

Current Analyst Ratings Breakdown

Latest ACRV, CABA, PRLD, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	PRLD Prelude Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/9/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/23/2026	CABA Cabaletta Bio	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/17/2026	PRLD Prelude Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$12.00
9/2/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00
8/24/2026	CABA Cabaletta Bio	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/14/2026	CABA Cabaletta Bio	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$4.00 ➝ $3.00
8/11/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.16 per share	N/A
FULC Fulcrum Therapeutics	$80M	3.50	N/A	N/A	$6.45 per share	0.57
PRLD Prelude Therapeutics	$12.14M	21.82	N/A	N/A	$1.09 per share	3.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	11/12/2026 (Estimated)
CABA Cabaletta Bio	-$167.86M	-$1.57	N/A	N/A	N/A	N/A	-128.27%	-95.47%	11/9/2026 (Estimated)
FULC Fulcrum Therapeutics	-$74.88M	-$1.21	N/A	N/A	N/A	N/A	-25.38%	-24.15%	10/29/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)

Latest ACRV, CABA, PRLD, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ACRV Acrivon Therapeutics	-$0.45	N/A	N/A	N/A	$0.50 million	N/A
11/11/2026	Q3 2026	PRLD Prelude Therapeutics	$0.0040	N/A	N/A	N/A	$29.00 million	N/A
11/9/2026	Q3 2026	CABA Cabaletta Bio	-$0.33	N/A	N/A	N/A	$1.67 million	N/A
10/29/2026	Q3 2026	FULC Fulcrum Therapeutics	-$0.0745	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	CABA Cabaletta Bio	-$0.3729	-$0.34	+$0.0329	-$0.34	$1.67 million	N/A
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
7/30/2026	Q2 2026	FULC Fulcrum Therapeutics	-$0.2433	-$0.34	-$0.0967	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	7.99
CABA Cabaletta Bio	N/A	5.79	5.79
FULC Fulcrum Therapeutics	N/A	31.35	31.35
PRLD Prelude Therapeutics	N/A	4.07	4.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
CABA Cabaletta Bio	N/A
FULC Fulcrum Therapeutics	89.83%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
CABA Cabaletta Bio	6.44%
FULC Fulcrum Therapeutics	7.30%
PRLD Prelude Therapeutics	49.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	76	42.85 million	38.35 million	Not Optionable
CABA Cabaletta Bio	158	169.54 million	158.63 million	Optionable
FULC Fulcrum Therapeutics	55	76.30 million	70.73 million	Optionable
PRLD Prelude Therapeutics	79	79.80 million	40.54 million	Optionable

ACRV, CABA, PRLD, and FULC Headlines

Recent News About These Companies

H.C. Wainwright keeps USD 8.00 target for Prelude Therapeutics stock

4 hours ago | ad-hoc-news.deA

Prelude Therapeutics Incorporated Proceeds With Phase 1 Study Of PRT13722 In Patients With HR+/HER2- Breast Cancer

October 14 at 7:49 PM | marketscreener.comM

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in ...

October 13 at 8:59 AM | markets.businessinsider.com

Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up

October 13 at 8:59 AM | rttnews.com

Prelude Therapeutics, Eli Lilly to Study Breast Cancer Drug Combinations in Phase 1 Trial

October 13 at 8:59 AM | finance.yahoo.com

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

October 13 at 7:01 AM | globenewswire.com

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated "Moderate Buy" by Sell-Side Analysts

October 1, 2026 | marketbeat.com

Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial

September 21, 2026 | ad-hoc-news.deA

Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Lowered by Wall Street Zen

September 19, 2026 | marketbeat.com

JPMorgan Chase & Co. Initiates Coverage on Prelude Therapeutics (NASDAQ:PRLD)

September 17, 2026 | marketbeat.com

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 11, 2026 | globenewswire.com

Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A ...

September 10, 2026 | finanznachrichten.de

Prelude Therapeutics Receives FDA Clearance For PRT13722 IND In HR+/HER2-Breast Cancer

September 10, 2026 | rttnews.com

Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial

September 10, 2026 | finance.yahoo.com

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

September 10, 2026 | globenewswire.com

Prelude Therapeutics: A Prognosis After Year-Long Rally

August 23, 2026 | seekingalpha.com

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | markets.businessinsider.com

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

July 31, 2026 | zacks.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

July 17, 2026 | zacks.com

Prelude Therapeutics

July 14, 2026 | fool.com

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, CABA, PRLD, and FULC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.76 +0.04 (+2.33%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.04 (+2.10%)

As of 10/15/2026 07:56 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Cabaletta Bio NASDAQ:CABA

$1.55 -0.07 (-4.32%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$1.57 +0.02 (+1.29%)

As of 10/15/2026 07:49 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Fulcrum Therapeutics NASDAQ:FULC

$3.67 0.00 (0.00%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$3.68 +0.00 (+0.14%)

As of 10/15/2026 07:30 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Prelude Therapeutics NASDAQ:PRLD

$3.32 +0.09 (+2.79%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$3.32 0.00 (0.00%)

As of 10/15/2026 07:30 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, CABA, PRLD, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, CABA, PRLD, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, CABA, PRLD, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, CABA, PRLD, and FULC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Cabaletta Bio NASDAQ:CABA

Fulcrum Therapeutics NASDAQ:FULC

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACRV, CABA, PRLD, and FULC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACRV, CABA, PRLD, and FULC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACRV, CABA, PRLD, and FULC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV, CABA, PRLD, and FULC Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Cabaletta Bio NASDAQ:CABA

Fulcrum Therapeutics NASDAQ:FULC

Prelude Therapeutics NASDAQ:PRLD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools